In addition, computational modeling and DNA pull‐down binding assays showed that APOE ɛ4, a key genetic risk factor for sporadic AD, may compete with TFEB for binding to CLEAR elements in the promoters of important genes involved in the ALP, including SQSTM1, MAP1LC3B, and LAMP2, thereby suggesting inhibition of the CLEAR network in APOE ɛ4/ɛ4 AD patients.113. The gene discussed is APOE; the disease is Alzheimer disease.